Literature DB >> 2969785

Characterization of the human interleukin 1 receptor on human polymorphonuclear leukocytes.

J A Rhyne1, S B Mizel, R G Taylor, M Chedid, C E McCall.   

Abstract

Interleukin 1 (IL-1) is a mediator of inflammation with multiple proinflammatory and immunologic enhancing activities. Human polymorphonuclear leukocytes (PMN) also play a major role in the inflammatory response. We have found that PMN possess a single type of high affinity receptor for human recombinant (r) IL-1 alpha with an apparent dissociation constant of 0.28 nM. Approximately 700 receptors are present per cell. Binding is rapid with 50% of maximal binding occurring within 20 min at 4 degrees C. Internalization of the receptor occurs within 25 min after shifting the cells to 37 degrees C. The receptor exhibits an apparent molecular weight of approximately 60-70 kDa. Electron microscopic autoradiography studies reveal that the 125I-rIL-1 alpha localized in the nucleus within 180 min after shifting cells to 37 degrees C. The accumulation of relatively high levels of 125I-rIL-1 alpha in the nucleus is consistent with earlier observations on the nuclear localization of IL-1 in T lymphocytes. The possibility that IL-1 may exert a direct action in the nucleus remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2969785     DOI: 10.1016/0090-1229(88)90029-3

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  17 in total

1.  In-vivo extravasation induces the expression of interleukin 1 receptor type 1 in human neutrophils.

Authors:  J M Paulsson; A Moshfegh; E Dadfar; C Held; S H Jacobson; J Lundahl
Journal:  Clin Exp Immunol       Date:  2012-04       Impact factor: 4.330

2.  Expression of interleukin-1 alpha and beta genes by human blood polymorphonuclear leukocytes.

Authors:  P C Lord; L M Wilmoth; S B Mizel; C E McCall
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

3.  Human tumour necrosis factor-alpha (TNF-alpha) directly stimulates arachidonic acid release in human neutrophils.

Authors:  Y H Atkinson; A W Murray; S Krilis; M A Vadas; A F Lopez
Journal:  Immunology       Date:  1990-05       Impact factor: 7.397

4.  Interleukin 1 stimulates phosphatidylinositol kinase activity in human fibroblasts.

Authors:  L R Ballou; S C Barker; A E Postlethwaite; A H Kang
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

5.  Interleukin 1 signaling occurs exclusively via the type I receptor.

Authors:  J E Sims; M A Gayle; J L Slack; M R Alderson; T A Bird; J G Giri; F Colotta; F Re; A Mantovani; K Shanebeck
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

6.  Human polymorphonuclear leucocytes stimulated by tumour necrosis factor-alpha show increased adherence to extracellular matrix proteins which is mediated via the CD11b/18 complex.

Authors:  H L Thompson; K Matsushima
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

7.  Interleukin 1 induces HIV-1 expression in chronically infected U1 cells: blockade by interleukin 1 receptor antagonist and tumor necrosis factor binding protein type 1.

Authors:  E V Granowitz; B M Saget; M Z Wang; C A Dinarello; P R Skolnik
Journal:  Mol Med       Date:  1995-09       Impact factor: 6.354

8.  Interleukin-1 down-regulates gene and surface expression of interleukin-1 receptor type I by destabilizing its mRNA whereas interleukin-2 increases its expression.

Authors:  K Ye; K C Koch; B D Clark; C A Dinarello
Journal:  Immunology       Date:  1992-03       Impact factor: 7.397

9.  Cytokine-induced neutrophil-derived interleukin-8.

Authors:  R M Strieter; K Kasahara; R M Allen; T J Standiford; M W Rolfe; F S Becker; S W Chensue; S L Kunkel
Journal:  Am J Pathol       Date:  1992-08       Impact factor: 4.307

10.  Modulation of leucocyte locomotion by interleukin-1.

Authors:  C C Zielinski; B Pesau; W Kalinowski; C Müller
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.